Joseph Stringer

Stock Analyst at Needham

(3.70)
# 769
Out of 4,911 analysts
306
Total ratings
44.81%
Success rate
8.61%
Average return

Stocks Rated by Joseph Stringer

Gilead Sciences
Jul 25, 2025
Upgrades: Buy
Price Target: $133
Current: $116.20
Upside: +14.46%
Rhythm Pharmaceuticals
Jul 9, 2025
Maintains: Buy
Price Target: $72$95
Current: $86.45
Upside: +9.89%
Stoke Therapeutics
Jul 1, 2025
Reiterates: Buy
Price Target: $22
Current: $13.10
Upside: +67.94%
Alnylam Pharmaceuticals
Jun 26, 2025
Maintains: Buy
Price Target: $320$377
Current: $328.81
Upside: +14.66%
Cidara Therapeutics
Jun 23, 2025
Maintains: Buy
Price Target: $36$54
Current: $61.85
Upside: -12.69%
Phathom Pharmaceuticals
Jun 6, 2025
Maintains: Buy
Price Target: $28
Current: $9.63
Upside: +190.76%
Vir Biotechnology
May 22, 2025
Reiterates: Buy
Price Target: $14
Current: $5.65
Upside: +147.79%
Annexon
May 13, 2025
Maintains: Buy
Price Target: $16$11
Current: $2.51
Upside: +338.25%
Apellis Pharmaceuticals
May 7, 2025
Maintains: Buy
Price Target: $40$29
Current: $19.59
Upside: +48.03%
Vertex Pharmaceuticals
May 6, 2025
Reiterates: Hold
Price Target: n/a
Current: $469.65
Upside: -
Maintains: Buy
Price Target: $60$55
Current: $42.25
Upside: +30.19%
Reiterates: Buy
Price Target: $60
Current: $36.27
Upside: +65.43%
Reiterates: Buy
Price Target: $90
Current: $36.63
Upside: +145.70%
Reiterates: Hold
Price Target: n/a
Current: $1.10
Upside: -
Downgrades: Hold
Price Target: $10
Current: $1.57
Upside: +536.94%
Reiterates: Hold
Price Target: n/a
Current: $34.15
Upside: -
Upgrades: Buy
Price Target: $37
Current: $23.25
Upside: +59.14%
Maintains: Buy
Price Target: $32$18
Current: $11.03
Upside: +63.19%